<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870869</url>
  </required_header>
  <id_info>
    <org_study_id>410CAXL-001</org_study_id>
    <nct_id>NCT01870869</nct_id>
  </id_info>
  <brief_title>NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study</brief_title>
  <official_title>NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, nonrandomized study to provide access to and
      evaluate the safety and effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped
      Silicone-Filled X-Style and L-Style Breast Implants for breast augmentation, reconstruction,
      or revision.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    There was no indication that long-term follow-up would differ between any of the studies that
    have evaluated devices within the 410 Style Matrix.
  </why_stopped>
  <start_date type="Actual">May 29, 2013</start_date>
  <completion_date type="Actual">November 30, 2015</completion_date>
  <primary_completion_date type="Actual">November 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants According to Investigator Satisfaction With Implants</measure>
    <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
    <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants According to Participant Satisfaction With Implants</measure>
    <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
    <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Local Complications</measure>
    <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Reoperations</measure>
    <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Implant Removal With or Without Replacement</measure>
    <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
    <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1951</enrollment>
  <condition>Breast Augmentation</condition>
  <condition>Breast Reconstruction</condition>
  <condition>Breast Implant Revision</condition>
  <arm_group>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection</intervention_name>
    <description>Surgical implant</description>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_label>Reconstruction</arm_group_label>
    <arm_group_label>Revision-Augmentation</arm_group_label>
    <arm_group_label>Revision-Reconstruction</arm_group_label>
    <other_name>NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants (Styles FX, MX, LX, FL, ML, LL, LM, and LF)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For entry in this study, participants must have either been enrolled in the 410 CA Clinical
        Study or 410 CARE Clinical Study under the inclusion criteria below and received NATRELLE®
        410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1
        or both breasts; or be planning to be implanted with NATRELLE® 410 Highly Cohesive
        Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and
        meet the inclusion criteria listed below:

          -  Female, age 18 or older (age 22 or older for breast augmentation participants who are
             implanted under Protocol 410CAXL-001)

          -  Present with 1 or more of the following conditions:

               -  Primary breast augmentation (i.e., no previous breast implant surgery) indicated
                  for participant dissatisfaction with size or shape of breast (e.g., mammary
                  hypoplasia), asymmetry, ptosis, or aplasia

               -  Primary breast reconstruction (i.e., no previous breast implant surgery other
                  than implantation of tissue expanders or contralateral augmentation for
                  asymmetry) indicated, in the affected breast, for mastectomy for cancer,
                  prophylactic mastectomy, or breast trauma, (resulting in mastectomy) and for the
                  unaffected breast, contralateral asymmetry (may be performed on the date of the
                  mastectomy or the date when permanent implants are placed in the reconstructed
                  breast)

               -  Breast implant revision surgery (i.e., removal and replacement of breast
                  implants) indicated for previous augmentation or reconstruction with
                  silicone-filled or saline-filled breast implants

          -  Has adequate tissue available to cover implants

        Exclusion Criteria:

        For entry in this study, participants must have either been enrolled in the 410 CA Clinical
        Study or 410 CARE Clinical Study and did not meet the exclusion criteria listed below or
        plan to undergo implantation with NATRELLE® 410 Highly Cohesive Anatomically Shaped
        Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and does not meet the
        exclusion criteria listed below:

          -  Has an advanced fibrocystic disease considered to be premalignant without accompanying
             subcutaneous mastectomy

          -  Has an existing carcinoma of the breast, without mastectomy

          -  Has an abscess or infection in the body at the time of enrollment

          -  Is pregnant or nursing

          -  Has any disease, including uncontrolled diabetes (e.g., hemoglobin A1c (HbA1c) &gt; 8%),
             that is clinically known to impact wound healing ability

          -  Shows tissue characteristics that are clinically incompatible with mammaplasty, such
             as tissue damage resulting from radiation, inadequate tissue, compromised vascularity,
             or ulceration

          -  Has or is under treatment for any condition that may constitute an unwarranted
             surgical risk (e.g., unstable cardiac or pulmonary problems)

          -  Shows psychological characteristics that may be incompatible with the surgical
             procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body
             dysmorphic disorder)

          -  Is not willing to undergo further surgery for revision, if medically required
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Schumacher</last_name>
    <role>Study Chair</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anthony Griffin</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurence Berkowitz</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Powers</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roy Hong</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eric Bachelor</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Douglas Reavie</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Teitelbaum</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tad Heinz</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary Snider</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terrence Murphy</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando De Lucia</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lewis Berger</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerard Mosiello</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Namnoum</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Johnson</name>
      <address>
        <city>Des Plaines</city>
        <state>Illinois</state>
        <zip>60016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Madry</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Janet Turkle</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruce Van Natta</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christine Kelley-Patteson</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brad Storm</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julene Samuels</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timothy Mickel</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Davis</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradley Bengtson</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Renucci</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steven Morris</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <zip>48640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Nathan</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herluf Lund Jr.</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patricia McGuire</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schuyler Meltis</name>
      <address>
        <city>Hannibal</city>
        <state>Missouri</state>
        <zip>63401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Johnson</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Johnson</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Hyans</name>
      <address>
        <city>Berkeley Heights</city>
        <state>New Jersey</state>
        <zip>07922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isaac Starker</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Hetzler</name>
      <address>
        <city>Little Silver</city>
        <state>New Jersey</state>
        <zip>07739</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc Alan Drimmer</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caroline Glicksman</name>
      <address>
        <city>Sea Girt</city>
        <state>New Jersey</state>
        <zip>08750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lloyd Gayle</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Sherman</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tracy Pfeifer</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Jacobs</name>
      <address>
        <city>Port Jefferson Station</city>
        <state>New York</state>
        <zip>11776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Decorato</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raymond Isakov</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Craig Colville</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank Barone</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derek Shadid</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Hein</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark Jewell</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Lettieri</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kristina D. O'Shaughnessy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patrick Maxwell</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Carpenter</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeffrey Friedman</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natan Yaker</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Adams</name>
      <address>
        <city>University Park</city>
        <state>Texas</state>
        <zip>75205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloria Duda</name>
      <address>
        <city>McLean</city>
        <state>Virginia</state>
        <zip>22101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gavin Dry</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allen Gabriel</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P2">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P3">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="P4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="206"/>
                <participants group_id="P3" count="1222"/>
                <participants group_id="P4" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="192"/>
                <participants group_id="P3" count="1092"/>
                <participants group_id="P4" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="130"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Implanted with nonstudy device</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject choice</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not evaluable</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
      <group_list>
        <group group_id="B1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B2">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B3">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="278"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="1180"/>
            <count group_id="B4" value="225"/>
            <count group_id="B5" value="1884"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Number analyzed is the number of participants with available age data.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="277"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="1176"/>
                    <count group_id="B4" value="223"/>
                    <count group_id="B5" value="1877"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" lower_limit="18.0" upper_limit="63.0"/>
                    <measurement group_id="B2" value="47.3" lower_limit="20.0" upper_limit="79.0"/>
                    <measurement group_id="B3" value="50.3" lower_limit="21.0" upper_limit="79.0"/>
                    <measurement group_id="B4" value="54.4" lower_limit="31.0" upper_limit="80.0"/>
                    <measurement group_id="B5" value="48.1" lower_limit="18.0" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="278"/>
                    <count group_id="B2" value="201"/>
                    <count group_id="B3" value="1180"/>
                    <count group_id="B4" value="225"/>
                    <count group_id="B5" value="1884"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="1180"/>
                    <measurement group_id="B4" value="225"/>
                    <measurement group_id="B5" value="1884"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants According to Investigator Satisfaction With Implants</title>
        <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
        <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
        <population>Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants According to Investigator Satisfaction With Implants</title>
          <description>The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
          <population>Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definitely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                    <measurement group_id="O2" value="85.3"/>
                    <measurement group_id="O3" value="74.1"/>
                    <measurement group_id="O4" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="21.5"/>
                    <measurement group_id="O4" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants According to Participant Satisfaction With Implants</title>
        <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
        <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
        <population>Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants According to Participant Satisfaction With Implants</title>
          <description>The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: &quot;Definitely satisfied&quot; or &quot;Somewhat satisfied&quot; is reported.</description>
          <population>Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="247"/>
                <count group_id="O4" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definitely satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3"/>
                    <measurement group_id="O2" value="76.5"/>
                    <measurement group_id="O3" value="68.0"/>
                    <measurement group_id="O4" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="24.7"/>
                    <measurement group_id="O4" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Local Complications</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .</description>
        <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
        <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local Complications</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications .</description>
          <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="1180"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.62" lower_limit="3.78" upper_limit="11.45"/>
                    <measurement group_id="O2" value="9.09" lower_limit="5.65" upper_limit="14.46"/>
                    <measurement group_id="O3" value="14.50" lower_limit="11.78" upper_limit="17.78"/>
                    <measurement group_id="O4" value="10.19" lower_limit="6.81" upper_limit="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymmetry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.26" upper_limit="4.73"/>
                    <measurement group_id="O2" value="1.99" lower_limit="0.75" upper_limit="5.21"/>
                    <measurement group_id="O3" value="2.34" lower_limit="1.59" upper_limit="3.44"/>
                    <measurement group_id="O4" value="2.67" lower_limit="1.21" upper_limit="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="0.51" upper_limit="7.15"/>
                    <measurement group_id="O2" value="1.08" lower_limit="0.15" upper_limit="7.39"/>
                    <measurement group_id="O3" value="0.51" lower_limit="0.23" upper_limit="1.13"/>
                    <measurement group_id="O4" value="1.07" lower_limit="0.26" upper_limit="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capsular contracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" lower_limit="0.68" upper_limit="4.98"/>
                    <measurement group_id="O2" value="7.90" lower_limit="3.57" upper_limit="17.01"/>
                    <measurement group_id="O3" value="20.14" lower_limit="8.90" upper_limit="41.85"/>
                    <measurement group_id="O4" value="27.03" lower_limit="9.04" upper_limit="64.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delayed wound healing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.07" upper_limit="3.48"/>
                    <measurement group_id="O3" value="0.34" lower_limit="0.13" upper_limit="0.90"/>
                    <measurement group_id="O4" value="1.78" lower_limit="0.67" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fluid accumulation/seroma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0.05" upper_limit="2.57"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.07" upper_limit="3.48"/>
                    <measurement group_id="O3" value="0.57" lower_limit="0.26" upper_limit="1.28"/>
                    <measurement group_id="O4" value="1.78" lower_limit="0.67" upper_limit="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.43"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.43" lower_limit="0.18" upper_limit="1.04"/>
                    <measurement group_id="O4" value="0.44" lower_limit="0.06" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertrophic scarring/other abnormal scarring</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.18" upper_limit="2.85"/>
                    <measurement group_id="O2" value="1.29" lower_limit="0.32" upper_limit="5.12"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.24" upper_limit="2.30"/>
                    <measurement group_id="O4" value="0.44" lower_limit="0.06" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant extrusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.40" upper_limit="2.38"/>
                    <measurement group_id="O4" value="0.60" lower_limit="0.08" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant malposition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" lower_limit="0.80" upper_limit="6.07"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.25" upper_limit="3.92"/>
                    <measurement group_id="O3" value="1.22" lower_limit="0.52" upper_limit="2.84"/>
                    <measurement group_id="O4" value="1.33" lower_limit="0.43" upper_limit="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant palpability/visibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.07" upper_limit="3.33"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.25" lower_limit="0.08" upper_limit="0.79"/>
                    <measurement group_id="O4" value="0.44" lower_limit="0.06" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Implant rupture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="0.67" upper_limit="6.75"/>
                    <measurement group_id="O2" value="6.15" lower_limit="1.77" upper_limit="20.22"/>
                    <measurement group_id="O3" value="2.03" lower_limit="0.91" upper_limit="4.50"/>
                    <measurement group_id="O4" value="3.84" lower_limit="1.39" upper_limit="10.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.05" upper_limit="2.53"/>
                    <measurement group_id="O2" value="1.49" lower_limit="0.48" upper_limit="4.56"/>
                    <measurement group_id="O3" value="1.21" lower_limit="0.72" upper_limit="2.04"/>
                    <measurement group_id="O4" value="3.18" lower_limit="1.53" upper_limit="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.07" upper_limit="3.48"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.29" upper_limit="2.38"/>
                    <measurement group_id="O4" value="3.31" lower_limit="1.01" upper_limit="10.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="0.05" upper_limit="2.53"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.08" lower_limit="0.01" upper_limit="0.60"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.18" upper_limit="2.85"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.04" upper_limit="0.68"/>
                    <measurement group_id="O4" value="0.44" lower_limit="0.06" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tissue/skin necrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.04" upper_limit="0.68"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.07" upper_limit="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper pole fullness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O4" value="0.44" lower_limit="0.06" upper_limit="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wrinkling/rippling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.07" upper_limit="3.48"/>
                    <measurement group_id="O3" value="1.61" lower_limit="0.78" upper_limit="3.33"/>
                    <measurement group_id="O4" value="0.00" lower_limit="0.00" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="0.45" upper_limit="4.70"/>
                    <measurement group_id="O2" value="2.99" lower_limit="1.35" upper_limit="6.52"/>
                    <measurement group_id="O3" value="4.37" lower_limit="2.94" upper_limit="6.46"/>
                    <measurement group_id="O4" value="1.43" lower_limit="0.46" upper_limit="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Reoperations</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
        <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
        <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reoperations</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported.</description>
          <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="1180"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.02" lower_limit="8.42" upper_limit="19.84"/>
                    <measurement group_id="O2" value="25.08" lower_limit="16.99" upper_limit="36.09"/>
                    <measurement group_id="O3" value="39.70" lower_limit="35.35" upper_limit="44.38"/>
                    <measurement group_id="O4" value="35.75" lower_limit="27.42" upper_limit="45.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Implant Removal With or Without Replacement</title>
        <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.</description>
        <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
        <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmentation</title>
            <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O2">
            <title>Revision-Augmentation</title>
            <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O3">
            <title>Reconstruction</title>
            <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
          <group group_id="O4">
            <title>Revision-Reconstruction</title>
            <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Implant Removal With or Without Replacement</title>
          <description>Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported.</description>
          <population>Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="1180"/>
                <count group_id="O4" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" lower_limit="3.80" upper_limit="13.31"/>
                    <measurement group_id="O2" value="19.09" lower_limit="11.12" upper_limit="31.66"/>
                    <measurement group_id="O3" value="19.54" lower_limit="15.79" upper_limit="24.03"/>
                    <measurement group_id="O4" value="20.59" lower_limit="13.59" upper_limit="30.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)</time_frame>
      <desc>Adverse events were not collected in this study. Deaths are reported as Serious Adverse Events. Specific local complications were collected and are reported in the Outcome Measure section. Evaluable population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Augmentation</title>
          <description>Women who had breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E2">
          <title>Revision-Augmentation</title>
          <description>Women who had revision of previous breast augmentation with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E3">
          <title>Reconstruction</title>
          <description>Women who had breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
        <group group_id="E4">
          <title>Revision-Reconstruction</title>
          <description>Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Recurrence of breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Liver cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="225"/>
              </event>
              <event>
                <sub_title>Metastatic breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1180"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="225"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area, Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

